Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

92 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Rationale and design of the pragmatic clinical trial tREatment with Beta-blockers after myOcardial infarction withOut reduced ejection fracTion (REBOOT).
Rossello X, Raposeiras-Roubin S, Latini R, Dominguez-Rodriguez A, Barrabés JA, Sánchez PL, Anguita M, Fernández-Vázquez F, Pascual-Figal D, De la Torre Hernandez JM, Ferraro S, Vetrano A, Pérez-Rivera JA, Prada-Delgado O, Escalera N, Staszewsky L, Pizarro G, Agüero J, Pocock S, Ottani F, Fuster V, Ibáñez B; REBOOT-CNIC investigators. Rossello X, et al. Among authors: staszewsky l. Eur Heart J Cardiovasc Pharmacother. 2022 May 5;8(3):291-301. doi: 10.1093/ehjcvp/pvab060. Eur Heart J Cardiovasc Pharmacother. 2022. PMID: 34351426 Clinical Trial.
Beneficial effects of angiotensin-converting enzyme inhibitor and nitrate association on left ventricular remodeling in patients with large acute myocardial infarction: the Delapril Remodeling after Acute Myocardial Infarction (DRAMI) trial.
Latini R, Staszewsky L, Maggioni AP, Marino P, Hernandez-Bernal F, Tognoni G, Labarta V, Gramenzi S, Bianchi F, Sarcina G, Cremonesi G, Nicolosi GL, Geraci E; Delapril Remodeling after Acute Myocardial Infarction Collaborative Group. Latini R, et al. Among authors: staszewsky l. Am Heart J. 2003 Jul;146(1):133. doi: 10.1016/S0002-8703(02)94777-0. Am Heart J. 2003. PMID: 12851621 Clinical Trial.
Valsartan for the treatment of heart failure.
Latini R, Masson S, Staszewsky L, Maggioni AP. Latini R, et al. Among authors: staszewsky l. Expert Opin Pharmacother. 2004 Jan;5(1):181-93. doi: 10.1517/14656566.5.1.181. Expert Opin Pharmacother. 2004. PMID: 14680446 Review.
Mesoangioblasts, vessel-associated multipotent stem cells, repair the infarcted heart by multiple cellular mechanisms: a comparison with bone marrow progenitors, fibroblasts, and endothelial cells.
Galli D, Innocenzi A, Staszewsky L, Zanetta L, Sampaolesi M, Bai A, Martinoli E, Carlo E, Balconi G, Fiordaliso F, Chimenti S, Cusella G, Dejana E, Cossu G, Latini R. Galli D, et al. Among authors: staszewsky l. Arterioscler Thromb Vasc Biol. 2005 Apr;25(4):692-7. doi: 10.1161/01.ATV.0000156402.52029.ce. Epub 2005 Jan 20. Arterioscler Thromb Vasc Biol. 2005. PMID: 15662021
Rationale and design of the GISSI-Atrial Fibrillation Trial: a randomized, prospective, multicentre study on the use of valsartan, an angiotensin II AT1-receptor blocker, in the prevention of atrial fibrillation recurrence.
Disertori M, Latini R, Maggioni AP, Delise P, Di Pasquale G, Franzosi MG, Staszewsky L, Tognoni G; GISSI-AF Investigators. Disertori M, et al. Among authors: staszewsky l. J Cardiovasc Med (Hagerstown). 2006 Jan;7(1):29-38. doi: 10.2459/01.JCM.0000199778.85343.08. J Cardiovasc Med (Hagerstown). 2006. PMID: 16645357 Clinical Trial.
92 results